EBV mRNA vaccine for HIV-related lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new mRNA vaccine that targets the Epstein-Barr virus (EBV) in people with HIV-related lymphoma. The goal is to see if the vaccine can help the immune system fight the cancer, especially for those whose lymphoma has not fully responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have HIV and a type of lymphoma (like DLBCL, Burkitt, or Hodgkin) that is EBV-positive
- You must have had at least one prior treatment for lymphoma and it did not work or you could not tolerate it
- You must be in fairly good health (ECOG score 0-2) and expected to live at least 3 months more
- You should not have other active cancers, serious heart issues, autoimmune diseases, or uncontrolled infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This study tests a new mRNA vaccine that helps your immune system fight cancer cells linked to the Epstein-Barr virus. It may be an option for people with advanced EBV-positive cancers that have not responded to standard treatments.
This trial tests an experimental cell therapy that targets cells infected with the Epstein-Barr virus (EBV). It is for patients with certain blood cancers or post-transplant lymph disorders caused by EBV that have not responded to standard treatments or who cannot receive them.
This trial tests nivolumab (an immune therapy) for people with EBV-positive lymphoma or EBV-driven immune/lymph conditions. It may help shrink tumors or control the disease when standard treatments have not worked or are not suitable.
Hear when a new HIV Associated Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.